Filing Flows › CytomX Therapeutics (CTMX) › Q3 2026 › vs Q2 2026
CytomX Therapeutics (CTMX) Q3 2026 vs Q2 2026 (quarter over quarter)
CytomX Therapeutics's revenue rose $270K (+19%) from $1.4M in Q2 2026 to $1.7M in Q3 2026.
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.7M | $1.4M | $270K | +19% |
| Other income, net | $3.6M | $3.2M | $390K | +12% |
| Net loss | $20.0M | $20.7M | −$668K | -3% |
| Costs & expenses | $25.3M | $25.3M | −$8K | 0% |
| Operating costs | $25.2M | $25.2M | −$9K | 0% |
| Income tax | $61K | $60K | $1K | +2% |
| Research & development | $16.5M | $17.6M | −$1.1M | -6% |
| General & admin | $8.7M | $7.6M | $1.1M | +15% |
| Operating cash sources | $36.6M | $2.6M | $34.0M | 14× |
| Share-based compensation | $2.8M | $2.6M | $266K | +10% |
| Working capital & other | $33.8M | $21K | $33.8M | 1,610× |
| Net loss absorbed | $20.0M | $20.7M | −$668K | -3% |
| Operating cash flow | $16.6M | −$18.1M | $34.7M | — |
| Free cash flow (OCF − capex) | $16.1M | −$18.1M | $34.1M | — |
| Capital expenditures | $589K | $0 | $589K | — |
Questions
How much did CytomX Therapeutics's revenue grow quarter over quarter in Q3 2026?
CytomX Therapeutics's revenue rose $270K (+19%) from $1.4M in Q2 2026 to $1.7M in Q3 2026.